Comparative study of human colonic tumor-derived endothelial cells (HCTEC) and normal colonic microvascular endothelial cells (HCMEC): Hypoxia-induced sVEGFR-1 and sVEGFR-2 levels

Oncology Reports

Volumn 21, Issue 4, 2009, Pages 933-939

  Jayasinghe, Caren ^a,b   Simiantonaki, Nektaria ^a,b   Michel Schmidt, Romi ^a   Kirkpatrick, Charles James ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

Author keywords

HCMEC; HCTEC; Hypoxia; sVEGFR 1; sVEGFR 2

Indexed keywords

BIOLOGICAL MARKER; CD31 ANTIGEN; COLLAGENASE; DISPASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 18; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; CANCER GROWTH; CANCER TISSUE; CELL ISOLATION; COLON TUMOR; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IN VITRO STUDY; MICROVASCULATURE; MONOLAYER CULTURE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR NECROSIS; TUMOR VASCULARIZATION; UPREGULATION; CELL CULTURE; CELL HYPOXIA; CELL SEPARATION; CHEMISTRY; COLON; CYTOLOGY; MICROCIRCULATION; VASCULARIZATION;

CELL HYPOXIA; CELL SEPARATION; CELLS, CULTURED; COLON; COLONIC NEOPLASMS; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MICROCIRCULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 67449107895     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000306     Document Type: Article

References (29)

1. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
2. Ribatti D: The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med 8: 294-300, 2004.
3. Hida K, Hida Y and Shindoh M: Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 99: 459-466, 2007.
4. Bussolati B, Deambrosis I, Russo S, Deregibus MC and Camussi G: Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 17: 1159-1161, 2003.
5. Allport JR and Weissleder R: Murine Lewis lung carcinoma-derived endothelium expresses markers of endothelial activation and requires tumor-specific extracellular matrix in vitro. Neoplasia 5: 205-217, 2003.
6. Schellerer VS, Croner RS, Weinländer K, Hohenberger W, Stürzl M and Naschberger E: Endothelial cells of human colorectal cancer and healthy colon reveal phenotypic differences in culture. Lab Invest 87: 1159-1170, 2007.
7. Toffoli S and Michiels C: Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. FEBS J 275: 2991-3002, 2008.
8. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
9. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
10. Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39: 469-478, 2006.
11. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM and Shibuya M: MMP9 induction by vascular endothelial growth factor receptor-1 is involved inlung-specific metastasis. Cancer Cell 2: 289-300, 2002.
12. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Charnock-Jones DS, Hicklin DJ, Herbert JM, Collen D and Persico MG: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 7: 575-583, 2001.
13. Shibuya M: Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int J Biochem Cell Biol 33: 409-420, 2001.
14. Artini PG, Ruggiero M, Monteleone P, Carpi A, Cristello F, Cela V and Genazzani AR: Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors. Biomed Pharmacother 62: 373-377, 2007.
15. Yilmaztepe A, Ulukaya E, Zik B, Yagci A, Sevimli A, Yilmaz M, Erdogan BB, Koc M, Akgoz S, Karadag M and Tokullugil A: Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) is decreased in lung cancer patients showing progression: a pilot study. Cancer Invest 25: 322-327, 2007.
16. Bando H, Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T and Toi M: Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 92: 553-561, 2005.
17. Chin KF, Greenman J, Reusch P, Gardiner E, Marme D and Monson JR: Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence. Eur J Surg Oncol 29: 497-505, 2003.
18. Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA and Curiel DT: Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 95: 8795-8000, 1998.
19. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X and Kerbel RS: A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2: 315-326, 2004.
20. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ and Kerbel RS: Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res 68: 521-529, 2008.
21. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ and Peters KG: Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9: 49-58, 1998.
22. Jayasinghe C, Simiantonaki N, Michel-Schmidt R and Kirkpatrick CJ: Hypoxia-induced reduction of sVEGFR-2 levels in human colonic microvascular endothelial cells (HCMEC) in vitro: Comparative study with HUVEC. Int J Mol Med 23: 49-55, 2009.
23. Tedder TF, Steeber DA, Chen A and Engel P: The selectins: vascular adhesion molecules. FASEB J 9: 866-873, 1995.
24. Wong D and Dorovini-Zis K: Regualtion by cytokines and lipopolysaccharide of E-selectin expression by human brain microvessel endothelial cells in primary culture. J Neuropathol Exp Neurol 55: 225-235, 1996.
25. Haraldsen G, Kvale D, Lien B, Farstad IN and Brandtzaeg P: Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol 156: 2558-2565, 1996.
26. Ugorski M and Laskowska A: Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim Pol 49: 303-311, 2002.
27. Ye C, Kiriyama K, Mistuoka C, Kannagi R, Ito K, Watanabe T, Kondo K, Akiyama S and Takagi H: Expression of E-selectin on endothelial cells of small veins in human colorectal cancer. Int J Cancer 61: 455-560, 1995.
28. Schoeffel U, Pelz K, Häring RU, Amberg R, Schandl R, Urbaschek R, von Specht BU and Farthmann EH: Inflammatory consequences of the translocation of bacteria and endotoxin to mesenteric lymph nodes. Am J Surg 180: 65-72, 2000.
29. Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM and Reinmuth N: Overview of angiogenesis: Biologic implications for antiangiogenic therapy. Semin Oncol 28: 94-104, 2001.